Simplify Asset Management Inc. Boosts Stake in Milestone Pharmaceuticals Inc. $MIST

by · The Cerbat Gem

Simplify Asset Management Inc. increased its stake in Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Free Report) by 186.2% in the 3rd quarter, Holdings Channel reports. The fund owned 2,832,974 shares of the company’s stock after buying an additional 1,842,974 shares during the quarter. Milestone Pharmaceuticals comprises about 0.1% of Simplify Asset Management Inc.’s holdings, making the stock its 29th largest position. Simplify Asset Management Inc.’s holdings in Milestone Pharmaceuticals were worth $5,666,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in MIST. Sapient Capital LLC bought a new stake in Milestone Pharmaceuticals during the third quarter worth about $25,000. Valeo Financial Advisors LLC raised its holdings in shares of Milestone Pharmaceuticals by 553.5% during the 2nd quarter. Valeo Financial Advisors LLC now owns 130,699 shares of the company’s stock valued at $254,000 after buying an additional 110,699 shares in the last quarter. Raymond James Financial Inc. raised its holdings in shares of Milestone Pharmaceuticals by 30.1% during the 2nd quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock valued at $84,000 after buying an additional 10,000 shares in the last quarter. XTX Topco Ltd lifted its position in Milestone Pharmaceuticals by 209.5% in the 2nd quarter. XTX Topco Ltd now owns 160,963 shares of the company’s stock worth $312,000 after buying an additional 108,959 shares during the last quarter. Finally, Creative Planning boosted its stake in Milestone Pharmaceuticals by 74.6% in the second quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after buying an additional 10,000 shares in the last quarter. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Stock Down 1.9%

NASDAQ MIST opened at $2.04 on Tuesday. Milestone Pharmaceuticals Inc. has a 1 year low of $0.63 and a 1 year high of $3.06. The stock has a market capitalization of $173.75 million, a PE ratio of -2.49 and a beta of 0.40. The company has a debt-to-equity ratio of 2.74, a current ratio of 8.24 and a quick ratio of 8.24. The business’s 50-day moving average is $2.20 and its 200 day moving average is $1.95.

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.05. Sell-side analysts forecast that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on MIST shares. Wall Street Zen raised shares of Milestone Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, December 21st. Wells Fargo & Company boosted their price target on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. HC Wainwright raised their price objective on Milestone Pharmaceuticals from $5.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 22nd. Finally, Cowen upgraded Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 15th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Read Our Latest Analysis on MIST

Milestone Pharmaceuticals Company Profile

(Free Report)

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.

Further Reading

Want to see what other hedge funds are holding MIST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Free Report).